Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis.

Farez MF, Correale J.

Arch Neurol. 2011 Oct;68(10):1267-71. doi: 10.1001/archneurol.2011.131. Epub 2011 Jun 13.

PMID:
21670384
2.

Review of the risks and benefits of yellow fever vaccination including some new analyses.

Monath TP.

Expert Rev Vaccines. 2012 Apr;11(4):427-48. doi: 10.1586/erv.12.6. Review.

PMID:
22551029
3.

Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.

Bar-Or A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo D, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H.

Arch Neurol. 2007 Oct;64(10):1407-15. Epub 2007 Aug 13.

PMID:
17698695
4.
5.

Yellow fever: the recurring plague.

Tomori O.

Crit Rev Clin Lab Sci. 2004;41(4):391-427. Review.

PMID:
15487593
6.

Prevention of yellow fever in persons traveling to the tropics.

Monath TP, Cetron MS.

Clin Infect Dis. 2002 May 15;34(10):1369-78. Epub 2002 Apr 25. Review. Erratum in: Clin Infect Dis 2002 Jul 1;35(1):110.

PMID:
11981733
7.

Late vaccination against yellow fever of travelers visiting endemic countries.

Krief I, Goldblatt JG, Paz A, Potasman I.

Travel Med Infect Dis. 2006 Mar;4(2):94-8.

PMID:
16887731
8.
9.

Yellow fever vaccine: an effective vaccine for travelers.

Verma R, Khanna P, Chawla S.

Hum Vaccin Immunother. 2014;10(1):126-8. doi: 10.4161/hv.26549. Epub 2013 Sep 20.

10.

17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.

Campi-Azevedo AC, de Araújo-Porto LP, Luiza-Silva M, Batista MA, Martins MA, Sathler-Avelar R, da Silveira-Lemos D, Camacho LA, de Menezes Martins R, de Lourdes de Sousa Maia M, Farias RH, da Silva Freire M, Galler R, Homma A, Ribeiro JG, Lemos JA, Auxiliadora-Martins M, Caldas IR, Elói-Santos SM, Teixeira-Carvalho A, Martins-Filho OA.

PLoS One. 2012;7(12):e49828. doi: 10.1371/journal.pone.0049828. Epub 2012 Dec 10.

11.

Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Staples JE, Gershman M, Fischer M; Centers for Disease Control and Prevention (CDC).

MMWR Recomm Rep. 2010 Jul 30;59(RR-7):1-27.

12.

Yellow fever vaccination coverage among children in Brazilian capitals.

Veras MA, Flannery B, de Moraes JC, da Silva Teixeira AM, Luna EJ; Vaccine Coverage Survey 2007 Group.

Vaccine. 2010 Sep 7;28(39):6478-82. doi: 10.1016/j.vaccine.2010.07.035. Epub 2010 Jul 30.

PMID:
20674878
13.

Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali.

Sidibe M, Yactayo S, Kalle A, Sall AA, Sow S, Ndoutabe M, Perea W, Avokey F, Lewis RF, Veit O.

Trans R Soc Trop Med Hyg. 2012 Jul;106(7):437-44. doi: 10.1016/j.trstmh.2012.04.002. Epub 2012 May 22.

PMID:
22627101
14.

Transfusion-related transmission of yellow fever vaccine virus--California, 2009.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 Jan 22;59(2):34-7.

15.

Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients.

Pistone T, Verdière CH, Receveur MC, Ezzedine K, Lafon ME, Malvy D.

Curr HIV Res. 2010 Sep;8(6):461-6.

PMID:
20636276
16.

Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients.

Sarchielli P, Di Filippo M, Candeliere A, Chiasserini D, Mattioni A, Tenaglia S, Bonucci M, Calabresi P.

J Neuroimmunol. 2007 Aug;188(1-2):146-58. Epub 2007 Jul 12.

PMID:
17628700
17.

Safety of the yellow Fever vaccine: a retrospective study.

Nordin JD, Parker ED, Vazquez-Benitez G, Kharbanda EO, Naleway A, Marcy SM, Molitor B, Kuckler L, Baggs J.

J Travel Med. 2013 Nov-Dec;20(6):368-73. doi: 10.1111/jtm.12070. Epub 2013 Oct 10.

18.

Transdermal application of myelin peptides in multiple sclerosis treatment.

Walczak A, Siger M, Ciach A, Szczepanik M, Selmaj K.

JAMA Neurol. 2013 Sep 1;70(9):1105-9. doi: 10.1001/jamaneurol.2013.3022.

PMID:
23817921
19.

Methodological issues with the risk of relapse study in patients with multiple sclerosis after yellow fever vaccination.

Pool V, Gordon DM, Decker M.

Arch Neurol. 2012 Jan;69(1):144; author reply 144-5. doi: 10.1001/archneurol.2011.1519. No abstract available.

PMID:
22232361
20.

Increase in multiple sclerosis activity after assisted reproduction technology.

Correale J, Farez MF, Ysrraelit MC.

Ann Neurol. 2012 Nov;72(5):682-94. doi: 10.1002/ana.23745. Epub 2012 Oct 3.

PMID:
23034952

Supplemental Content

Support Center